Current and future immunotherapies for thyroid cancer

References

• Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–129.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Forde PM, Hammers HJ, et al. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587–600.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meet immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013;13:5.
   PubMedGoogle Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Marincola FM. What have we learned from cancer immunotherapy in the last 3 years? J Transl Med. 2014;12:141.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33:2013–2020.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004–2012.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2- year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558–1568.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Aguiar PN Jr, De Mello RA, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9:499–506.
   PubMed Web of Science ®Google Scholar
• Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24:2911–2915.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119:3687–3695.
   PubMed Web of Science ®Google Scholar
• Kelderman S, van der Kooij MK, van den Eertwegh AJ, et al. Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013;52:1786–1788.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Vaubel J, Morh P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One. 2015;10:e0118564.
   PubMed Web of Science ®Google Scholar
• Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50:121–127.
   PubMed Web of Science ®Google Scholar
• Postow MA, Luke JJ, Bluth MJ, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013;18:726–732.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-work efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Addeo R, Carteni G, et al. The role of immunotherapy in solid tumors: report of the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med. 2014;12:291.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2017 Aug 11. pii: clincanres.3001.2017.
   PubMedGoogle Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
   PubMed Web of Science ®Google Scholar
• Roberts K, Culleton V, Lwin Z, et al. Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol. 2017;13:277–288.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497–1508.
   PubMed Web of Science ®Google Scholar
• Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361–1375.
   PubMed Web of Science ®Google Scholar
• Joshi MN, Whitelaw BC, Palomar MTP, et al. Immune checkpoint inhibitor related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol. 2016;85:331–339.
   PubMed Web of Science ®Google Scholar
• Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195–207.
   PubMed Web of Science ®Google Scholar
• Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4:560–575.
   PubMed Web of Science ®Google Scholar
• Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303–307.
   PubMed Web of Science ®Google Scholar
• Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011;27:e87–8.
   PubMed Web of Science ®Google Scholar
• Alhusseini M, Samantray J. Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms. Exp Clin Endocrinol Diabetes. 2017;125:267–269.
   PubMed Web of Science ®Google Scholar
• Brilli L, Danielli R, Ciuoli C, et al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017;58:535–541.
   PubMed Web of Science ®Google Scholar
• Orlov S, Salari F, Kashat L, et al. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100:1738–1741.
   PubMed Web of Science ®Google Scholar
• De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5:312–318.
   PubMed Web of Science ®Google Scholar
• Shang YH, Zhang Y, Li JH, et al. Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. Immunotherapy. 2017;9:261–272.
   PubMed Web of Science ®Google Scholar
• Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28:583–589.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, Paragliola R, et al. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid. 2013;23:1345–1366.
   PubMed Web of Science ®Google Scholar
• De Remigis A, de Gruijl TD, Uram JN, et al. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer. 2015;136:127–137.
   PubMed Web of Science ®Google Scholar
• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559–574.
   PubMed Web of Science ®Google Scholar
• Merck. 2014. Pembrolizumab US full prescribing information. [cited Apr]. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
   Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–2391.
   PubMed Web of Science ®Google Scholar
• Genentech. 2016. Atezolizumab US full prescribing information. cited Apr. Available from: http://www.gene.com/download/pdf/tecentriq_prescribing.pdf
   Google Scholar
• Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer. Front Endocrinol (Lausanne). 2015;6:176.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Mazzi V, Vita R, et al. New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci. 2015;16:6153–6182.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272–280.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Frascerra S, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves’ and normal thyrocytes. J Clin Endocrinol Metab. 2010;95:E413–E420.
   PubMed Web of Science ®Google Scholar
• Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC–RAS–BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Investig. 2005;115:1068–1081.
   PubMed Web of Science ®Google Scholar
• Puxeddu E, Knauf JA, Sartor MA, et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer. 2005;12:319–334.
   PubMed Web of Science ®Google Scholar
• McCall KD, Harii N, Lewis CJ, et al. High basal levels of functional Toll-like receptor 3 (TLR3) and noncano- nical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology. 2007;148:4226–4237.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer. 2009;16:1299–1311.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine. 2012;59:218–222.
   PubMed Web of Science ®Google Scholar
• Wennerberg E, Pfefferle A, Ekblad L, et al. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. Clin Cancer Res. 2014;20:5733–5744.
   PubMed Web of Science ®Google Scholar
• Melillo RM, Guarino V, Avilla E, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29:6203–6215.
   PubMedGoogle Scholar
• González HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer. Thyroid. 2009;19:957–965.
   PubMed Web of Science ®Google Scholar
• Visciano C, Prevete N, Liotti F, et al. Tumor-associated mast cells in thyroid cancer. Int J Endocrinol. 2015;2015:705169.
   Google Scholar
• Rotondi M, Coperchini F, Awwad O, et al. Effect of interferon-γ on the basal and the TNFα-stimulated secretion of CXCL8 in thyroid cancer cell lines bearing either the RET/PTC rearrangement or the BRAF V600e mutation. Mediators Inflamm. 2016;2016:8512417.
   Google Scholar
• Ferrari SM, Elia G, Piaggi S, et al. CCL2 is modulated by cytokines and PPAR-g in anaplastic thyroid cancer. Anticancer Agents Med Chem. 2017. published online 19 July 2017.
   PubMedGoogle Scholar
• French JD, Kotnis GR, Said S, et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab. 2012;97:E934–E943.
   PubMed Web of Science ®Google Scholar
• Brauner E, Gunda V, Vanden Borre P, et al. Combining BRAF inhibitor and anti-PD-L1 antibody dramatically improves tumor regression and anti-tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7:17194–17211.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016;7:32318–32328.
   PubMed Web of Science ®Google Scholar
• French JD, Bible K, Spitzweg C, et al. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017;5:469–481.
   PubMed Web of Science ®Google Scholar
• Bai Y, Niu D, Huang X, et al. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagn Pathol. 2017;12:72.
   PubMed Web of Science ®Google Scholar
• Bongiovanni M, Rebecchini C, Saglietti C, et al. Very low expression of PD-L1 in medullary thyroid carcinoma. Endocr Relat Cancer. 2017;24:L35–L38.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One. 2016;11:e0161779.
   PubMed Web of Science ®Google Scholar
• Mellman I, Hubbard-Lucey VM, Tontonoz MJ, et al. De-risking immunotherapy: report of a consensus workshop of the cancer immunotherapy consortium of the Cancer Research Institute. Cancer Immunol Res. 2016;4:279–288.
   PubMed Web of Science ®Google Scholar
• Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35.
   PubMed Web of Science ®Google Scholar
• Vanden Borre P, Gunda V, McFadden DG, et al. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget. 2014;5:3996–4010.
   PubMed Web of Science ®Google Scholar
• Gunda V, Frederick DT, Bernasconi MJ, et al. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid. 2014;24:1241–1250.
   PubMed Web of Science ®Google Scholar
• Zhu L, Li XJ, Kalimuthu S, et al. Natural Killer Cell (NK-92MI)-based therapy for pulmonary metastasis of anaplastic thyroid cancer in a nude mouse model. Front Immunol. 2017;8:816.
   PubMed Web of Science ®Google Scholar
• Haupt K, Siegel F, Lu M, et al. Induction of a cellular and humoral immune response against preprocalcitonin by genetic i: a potential new treatment for medullary thyroid carcinoma. Endocrinology. 2001;142:1017–1023.
   PubMed Web of Science ®Google Scholar
• Gerfo PL, Feind C, Weber C, et al. Immunotherapy of thyroid cancer by induction of autoimmune thyroiditis. Surgery. 1983;94:959–965.
   PubMed Web of Science ®Google Scholar
• Schott M. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer. 2006;13:779–795.
   PubMed Web of Science ®Google Scholar
• Passaro C, Borriello F, Vastolo V, et al. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget. 2016;7:1500–1515.
   PubMed Web of Science ®Google Scholar
• Kollipara R, Schneider B, Radovich M, et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist. 2017;22:1149–1151.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Di Bari F, Ferrari SM, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015;9:3459–3470.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Politti U, Spisni R, et al. Sorafenib in the treatment of thyroid cancer. Expert Rev Anticancer Ther. 2015;15:863–874.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Di Bari F, et al. Cabozantinib in thyroid cancer. Recent Pat Anticancer Drug Discov. 2015;10:259–269.
   PubMed Web of Science ®Google Scholar
• Zhang T, Xie J, Arai S, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7:73068–73079.
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
   PubMed Web of Science ®Google Scholar